Home Compounds Growth Hormone Axis HGH Fragment 176-191
Growth Hormone Axis Research Preliminary

HGH Fragment 176-191

C-terminal fragment of HGH. Studied for isolated lipolytic activity, separating fat-burning effects from growth-promoting and anti-insulin effects of full HGH.

hgh fragmentlipolysisfat lossbody compositionselective
Half-life
30 minutes to 2 hours
SKUs
1
Evidence
Preliminary

HGH Fragment 176-191 is the C-terminal fragment of human growth hormone, consisting of amino acids 176 through 191. It was studied for lipolytic (fat-breaking) activity separate from HGH's growth-promoting effects. Human clinical trials were conducted but the compound did not meet its phase 3 endpoints for weight management.

Lipolysis Research
The fragment was designed based on the finding that the lipolytic activity of HGH resides primarily in its C-terminal region. Animal studies showed significant fat reduction with the fragment while avoiding growth effects and blood sugar disruption associated with full HGH.
Obesity Clinical Trials
Phase 2 and phase 3 human trials were conducted for weight management. The phase 3 trial failed to meet primary endpoints for weight loss versus placebo, leading the developer to discontinue the obesity program.
Joint and Cartilage Research
After the obesity program was discontinued, research interest shifted to musculoskeletal applications. The fragment received GRAS status in the US for use as a food ingredient, and some research explored cartilage regeneration properties in osteoarthritis models.
  • Demonstrates lipolysis stimulation in animal models without insulin-disrupting effects of full HGH.
  • Phase 3 human trial for obesity did not meet primary weight loss endpoints.
  • Generally well-tolerated in trials; GRAS status granted for food ingredient use.
  • Limited preclinical evidence for cartilage regeneration.

The human clinical trial failure for weight management is the defining context for this compound. Animal lipolytic effects did not translate into meaningful weight loss in the controlled human trial. It is not FDA-approved as a pharmaceutical and does not have an established indication. The GRAS status refers to food ingredient safety, not pharmaceutical efficacy.

HGH is a 191 amino acid protein. Different regions of the molecule are responsible for different effects. The growth-promoting effects come from one part; the fat-burning stimulation comes primarily from the C-terminal end, specifically around amino acids 176-191. This fragment is believed to interact with beta-3 adrenergic receptors in fat tissue, triggering lipolysis — the breakdown of fat stores into free fatty acids. By isolating just this region of the HGH molecule, researchers hoped to capture the fat-burning effect without triggering growth or blood sugar changes. The fragment worked this way in animal models. In the human obesity trial, however, the weight loss signal was not strong enough to outperform placebo in the controlled setting.

Well-tolerated in clinical trials. Not FDA-approved as a medication. GRAS designation for food use does not imply drug-level safety evaluation for any indication. Research-grade material purity and sterility are important practical considerations for any research use.

Preliminary

Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.

Published Research Ranges
250–500mcg 2x daily in research literature
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

The C-Terminal Fragment of Growth Hormone Stimulates Lipolysis In Vivo
Journal of Biological Chemistry • 1996  • DOI: 10.1074/jbc.271.40.24782
View Source
Differential Lipolytic and Anabolic Effects of Truncated HGH Analogues
Endocrinology • 2001  • DOI: 10.1210/endo.142.8.8416
View Source
NF-κB in biology and targeted therapy: new insights and translational implications
 • 2024  • DOI: 10.1038/s41392-024-01757-9
View Source
Growth hormone proteoformics atlas created to promote predictive, preventive, and personalized approach in overall management of pituitary neuroendocrine tumors
 • 2023  • DOI: 10.1007/s13167-023-00329-1
View Source
Human organs-on-chips for disease modelling, drug development and personalized medicine
 • 2022  • DOI: 10.1038/s41576-022-00466-9
View Source
Endoplasmic reticulum stress signals in the tumour and its microenvironment
 • 2021  • DOI: 10.1038/s41568-020-00312-2
View Source
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
 • 2019  • DOI: 10.1038/s41569-019-0169-2
View Source
Growth hormone: isoforms, clinical aspects and assays interference
 • 2018  • DOI: 10.1186/s40842-018-0068-1
View Source
Liposomal Formulations in Clinical Use: An Updated Review
 • 2017  • DOI: 10.3390/pharmaceutics9020012
View Source
Apoptotic cell clearance: basic biology and therapeutic potential
 • 2014  • DOI: 10.1038/nri3607
View Source
Obesity pharmacotherapy: current perspectives and future directions
 • 2013  • DOI: 10.2174/157340313805076322
View Source
Bile acid metabolism and signaling
 • 2013  • DOI: 10.1002/cphy.c120023
View Source
Regulation of intestinal epithelial permeability by tight junctions
 • 2013  • DOI: 10.1007/s00018-012-1070-x
View Source
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME
 • 2013  • DOI: 10.1007/s00204-013-1078-5
View Source
Guidelines for the use and interpretation of assays for monitoring autophagy
 • 2012  • DOI: 10.4161/auto.19496
View Source
Mitochondria: in sickness and in health
 • 2012  • DOI: 10.1016/j.cell.2012.02.035
View Source
Mechanisms for insulin resistance: common threads and missing links
 • 2012  • DOI: 10.1016/j.cell.2012.02.017
View Source
Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease
 • 2011  • DOI: 10.1146/annurev-biochem-060608-102511
View Source
Macrophage-mediated inflammation in metabolic disease
 • 2011  • DOI: 10.1038/nri3071
View Source
Pharmacological treatment of obesity in children and adolescents: present and future
 • 2011  • DOI: 10.1155/2011/928165
View Source
Factors affecting wound healing
 • 2010  • DOI: 10.1177/0022034509359125
View Source
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease
 • 2010  • DOI: 10.1016/j.cell.2010.02.034
View Source
The FGF family: biology, pathophysiology and therapy
 • 2009  • DOI: 10.1038/nrd2792
View Source
Transport and release of chemicals from plastics to the environment and to wildlife
 • 2009  • DOI: 10.1098/rstb.2008.0284
View Source
What can we learn from rodents about prolactin in humans?
 • 2008  • DOI: 10.1210/er.2007-0017
View Source
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver
 • 2008  • DOI: 10.1152/physrev.00013.2007
View Source
Redox regulation of cell survival
 • 2008  • DOI: 10.1089/ars.2007.1957
View Source
Adipose-derived stem cells for regenerative medicine
 • 2007  • DOI: 10.1161/01.res.0000265074.83288.09
View Source
A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine
 • 2005  • DOI: 10.1146/annurev.genet.39.110304.095751
View Source
Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells
 • 2024  • DOI: 10.1007/s00253-024-13008-6
View Source
Molecular recognition of peptides and proteins by cucurbit[n]urils: systems and applications
 • 2024  • DOI: 10.1039/d4cs00569d
View Source
Exploring treatment options in cancer: Tumor treatment strategies
 • 2024  • DOI: 10.1038/s41392-024-01856-7
View Source
A Comprehensive Review on Steroidal Bioconjugates as Promising Leads in Drug Discovery
 • 2022  • DOI: 10.1021/acsbiomedchemau.1c00071
View Source
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
 • 2022  • DOI: 10.1002/mco2.161
View Source
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
 • 2020  • DOI: 10.1038/s41392-019-0089-y
View Source
Recent advances in the formulation of PLGA microparticles for controlled drug delivery
 • 2020  • DOI: 10.1007/s40204-020-00139-y
View Source
Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies
 • 2020  • DOI: 10.3389/fbioe.2020.00089
View Source
Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals
 • 2020  • DOI: 10.3390/pharmaceutics12121184
View Source
Oral Delivery of Biologics via the Intestine
 • 2020  • DOI: 10.3390/pharmaceutics13010018
View Source
PARP and PARG inhibitors in cancer treatment
 • 2020  • DOI: 10.1101/gad.334516.119
View Source
Cellular signalling by primary cilia in development, organ function and disease
 • 2019  • DOI: 10.1038/s41581-019-0116-9
View Source
Type 1 diabetes
 • 2018  • DOI: 10.1016/s0140-6736(18)31320-5
View Source
Unraveling the Complex Interplay Between T Cell Metabolism and Function
 • 2018  • DOI: 10.1146/annurev-immunol-042617-053019
View Source
Developing Gram-negative bacteria for the secretion of heterologous proteins
 • 2018  • DOI: 10.1186/s12934-018-1041-5
View Source
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease
 • 2018  • DOI: 10.1016/bs.apha.2017.08.002
View Source
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
 • 2018  • DOI: 10.1158/1535-7163.mct-17-0646
View Source
Aptamers as targeted therapeutics: current potential and challenges
 • 2017  • DOI: 10.1038/nrd.2016.199
View Source
Induced protein degradation: an emerging drug discovery paradigm
 • 2017  • DOI: 10.1038/nrd.2016.211
View Source
Estrogens and Androgens in Skeletal Physiology and Pathophysiology
 • 2017  • DOI: 10.1152/physrev.00033.2015
View Source
Kidney stones
 • 2016  • DOI: 10.1038/nrdp.2016.8
View Source
Role of Recombinant DNA Technology to Improve Life
 • 2016  • DOI: 10.1155/2016/2405954
View Source
Biopharmaceuticals from microorganisms: from production to purification
 • 2016  • DOI: 10.1016/j.bjm.2016.10.007
View Source
Endothelin
 • 2016  • DOI: 10.1124/pr.115.011833
View Source
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential
 • 2015  • DOI: 10.1124/pr.114.009654
View Source
Protein-polymer conjugation-moving beyond PEGylation
 • 2015  • DOI: 10.1016/j.cbpa.2015.08.009
View Source
Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes
 • 2015  • DOI: 10.1002/anie.201412070
View Source
Computational methods in drug discovery
 • 2014  • DOI: 10.1124/pr.112.007336
View Source
Bile acid signaling in metabolic disease and drug therapy
 • 2014  • DOI: 10.1124/pr.113.008201
View Source
Therapeutic applications of an expanded genetic code
 • 2014  • DOI: 10.1002/cbic.201402154
View Source
Small-molecule inhibitors of protein-protein interactions: progressing toward the reality
 • 2014  • DOI: 10.1016/j.chembiol.2014.09.001
View Source

60 sources · Platform research library · Not generated by AI

FR5

Combination use is not endorsed - provided for research context only.

Want More Detailed Research?

Ask the AI anything about HGH Fragment 176-191 - mechanisms, trial summaries, pharmacokinetics, and comparisons.

Ask AI About HGH Fragment 176-191
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.